Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Healthcare Biotechnology
Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Theratechnologies Inc > Any analyst downgrades
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(48)
•••
Comment by SPCEO1on Jul 13, 2023 11:36pm
142 Views
Post# 35540628

RE:RE:RE:Any analyst downgrades

RE:RE:RE:Any analyst downgradesPaul was pretty clear that they wil be more transparent with the restarted trial/ If there is good ionfo coming out of the first few patients, I think we will hear about it in the Fall. IF we don't hear about it, then there is likely cause for some concern.
Trogarzon wrote: Ok thanks... next milestone July 28 to see what happens with Marathon, then august for share issue and consolidation for Nasdaq.. and then what we wait for F8 filing in September and then mid 2024 for cancer data... and then the AGM.. lol. When was the last good surprise we got.. 2018... any deal Paul.. too late for that and too early for that now.  Why should anyone buy a single share of Thera now... why.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities